2023 SABCS Posters

The molecules presented are investigational. Safety and efficacy have not been established.

BL-M07D1, a novel HER2 antibody-drug conjugate, in subjects with locally advanced or metastatic HER2 expressing breast cancer and other solid tumors: Results from a phase 1 study